

Preferential eradication of gram-negative bacteria using peptide surrogates: cisions & reflections

Shimon Shatzmiller*, Ludmila Buzhansky, Rami Krieger, Inbal Lapidot, Galina M. Zats and Marina Kovaliov

Department of Chemical Sciences, Ariel University, Ariel, Israel.

Corresponding author

Shimon Shatzmiller, Department of Chemical Sciences, Ariel University, Ariel, Israel.

Submitted: 01 Aug 2022; Accepted: 06 Aug 2022; Published: 16 Aug 2022

Citation: Shimon Shatzmiller, Ludmila Buzhansky, Rami Krieger, Inbal Lapidot, Galina M. Zats and Marina Kovaliov (2022) Preferential eradication of gram-negative bacteria using peptide surrogates: cisions & reflections. *Medical & Clinical Research* 7(8):01-13.

Abstract

Short surrogates of the pentapeptide K-A-A-A-K, centered on Freidinger's lactam, were applied to eradicate *E. coli* (Gram-negative bacteria) and *S. Aureus* (Gram-positive microbe). It was found that it was easier to eliminate the gram-positive bacteria, which was influenced by the N-methylation of the amide nitrogen of 30 → 31 (Table). However, The N-methylated surrogates were more efficient in eradicating the *E. coli* than the *S. Aureus* samples. We were able (Figure 14) to show that one structural change could make a remarkable difference in the eradication (MIC) of the different bacteria.

Introduction

The gut microbes of the Otzi the Iceman, a 5,300-year-old mummy found frozen in a European glacier in 1991 have shed new light on the history of human migration, scientists say [4]. "We can say now that the waves of migration that brought these African *Helicobacter pylori* into Europe had not occurred, or at least not occurred in earnest, by the time the Iceman was around." About half the people on the planet have the bacterium in their stomachs. It can cause ulcers or gastrointestinal distress and is typically spread among children when they play in the dirt.

It has been increasing for as long as the Centers for Disease Control and Prevention (CDC) has measured the prevalence of hospital-acquired infections caused by multidrug-resistant organisms [5]. According to the CDC, more than 70% of the bacteria now causing hospital-acquired infections (HAI) are resistant to at least one of the most commonly used drugs [6] It seems essential to control these infections because they have been more costly and deadly than those due to antibiotic-susceptible strains of the same species [6-9] Nevertheless, despite decades of discussing the control of antibiotic-resistant nosocomial infections, there has been little evidence of control in most healthcare facilities in most countries. Several articles in this issue of *Infection Control and Hospital Epidemiology* evaluate the efforts made by hospitals to control them and explain this failure [8].

From early this decade [9], Enterobacteriaceae that produce *Klebsiella pneumoniae* [10] carbapenemases (KPC) was reported in the USA and subsequently worldwide. This KPC-producing bacteria is predominantly involved in nosocomial and systemic infections [11]; although they are mostly Enterobacteriaceae, they can rarely be *Pseudomonas aeruginosa*, isolates. KPC β lactamases

(KPC-1 to KPC-7) confer decreased susceptibility or resistance to virtually all β lactams. The carbapenems are a class of beta-lactam antibiotics. They are active against many aerobic and anaerobic gram-positive and gram-negative bacteria. Imipenem, meropenem and ertapenem. Those may thus become inefficient for treating enterobacterial infections with KPC-producing bacteria. They resist many other non-β-lactam molecules, leaving few therapeutic options available. Detection of KPC-producing bacteria may be difficult based on routine antibiotic susceptibility testing. Therefore, it is crucial to implement efficient infection control measures to limit the spread of these pathogens. One of the most urgent issues in modern healthcare: is the global antibiotic resistance pandemic. Current estimates place the annual deaths from antibiotic-resistant bacteria at around 700,000 worldwide. Unless things change, this figure is predicted to rise to 10 million by 2050, with growing numbers of bacteria already fully resistant to every clinical antibiotic available [12].

It has been increasing for as long as the Centers for Disease Control and Prevention (CDC) has measured the prevalence of hospital-acquired infections caused by multidrug-resistant organism [13]. Hospital-acquired infections (HAI) have been recognized for over a century as a critical problem affecting healthcare quality. They constitute a significant source of adverse healthcare outcomes [14]. The emergence of multidrug-resistant bacteria (MDRB) has become a public health problem, creating a new burden on medical care in hospitals, particularly for patients admitted to intensive care units (ICU). Excessive and improper use of broad-spectrum antibiotics, especially in healthcare settings, elevates nosocomial infections, becoming a big health care problem, and causes tremendous economic and production loss in the community.

According to the CDC, more than 70% of the bacteria now causing hospital-acquired infections are resistant to at least one of the drugs most commonly used to treat them [15].

New strands of pathogenic bacteria cause the nosocomial pandemic all over the world [16,17].

WHO names 12 bacteria that pose the greatest threat to human health

- **The WHO list**
- Three bacteria are considered to be of critical priority:
 - *Pseudomonas aeruginosa*, carbapenem-resistant
 - *Staphylococcus aureus*, methicillin-resistant, vancomycin-intermediate and resistant
 - *Helicobacter pylori*, clarithromycin-resistant
- *Enterobacteriaceae*, carbapenem-resistant, ESBL-producing
- *Acinetobacter baumannii*, carbapenem-resistant
- *Salmonellae*, fluoroquinolone-resistant
- Several species of *Campylobacter*, fluoroquinolone-resistant
- Six are considered to be of high priority:
 - *Neisseria gonorrhoeae*, cephalosporin-resistant, fluoroquinolone-resistant
- *Enterococcus faecium*, vancomycin-resistant
- Three are deemed to be of medium priority:
 - *Streptococcus pneumoniae*, penicillin-non-susceptible

In a recent report published in Lancet Infectious Diseases, scientists discovered colistin-resistant E coli in 21percent of slaughtered pigs in China. They found isolates in 15 percent of meat sold from those animals in retail sites. They even detected resistant E Coli in more than 1 percent of hospitalized patients.

Most horrifying, it appears that plasmids transmit the resistance. That means the bacteria don't just pass on resistance to their "children"; they can pass it among one another and completely different bacteria strains. Scientists were also able to detect colistin resistance from the same gene in *Klebsiella pneumonia* in hospitalized patients. The accompanying editorial to the colistin report called this "a major breach in our last line of defense."

These bugs are mainly the products of genetic Transformation in the process of Horizontal gene transfer. Swapping genetic material between neighboring "contemporary" bacteria is another way resistance can be acquired. Many antibiotic resistance genes are carried on plasmids, transposons, or integrons that can act as vectors that transfer these genes to other members of the same bacterial species and bacteria in another genus or species. Horizontal gene transfer may occur via three main mechanisms: Transformation, transduction or conjugation.

- ❖ **Transformation** involves the uptake of short fragments of naked DNA by naturally transformable bacteria.
- ❖ **Transduction** involves the transfer of DNA from one bacterium into another via bacteriophages.
- ❖ **Conjugation** involves the transfer of DNA via sexual pilus and requires cell-to-cell contact. DNA fragments containing resistant donors' resistance genes can then make previously susceptible bacteria express resistance as coded by these newly acquired resistance genes [18].




Figure 1: Ways for bacterial Transformation.

Let's Look at Vertical Gene Transfer -how Genes are Passed from One Generation to the Next

For both bacteria and humans (and all other animals made of cells), genes are passed down to generations through DNA, the helix-shaped molecules that tell the protein-making machinery in cells what to build. Bacteria, made up of only one cell, have their DNA and reproduce by dividing into two sister cells, each with the same DNA. In this way, DNA is passed on to the next generation as an almost perfect copy. Even humans started off very much like this single-celled bacterium: When we were but a tiny fertilized egg in our mother's womb, we were just a single cell that split into two, then four, then eight cells, each with the same DNA. While humans then develop specialized cells that become our trillion-celled bodies, bacteria are single-cell organisms. Their lifecycle is limited to single cells splitting into more single cells repeatedly. Each [19] split is a new generation.

Bacterium	Medium	Generation Time (minutes)
<i>Escherichia coli</i>	Glucose-salts	17
<i>Bacillus megaterium</i>	Sucrose-salts	25
<i>Streptococcus lactis</i>	Milk	26
<i>Streptococcus lactis</i>	Lactose broth	48
<i>Staphylococcus aureus</i>	Heart infusion broth	27-30
<i>Lactobacillus acidophilus</i>	Milk	66-87
<i>Rhizobium japonicum</i>	Mannitol-salts-yeast extract	344-461
<i>Mycobacterium tuberculosis</i>	Synthetic	792-932
<i>Treponema pallidum</i>	Rabbit testes	1980

Figure 2: Generation times for some common bacteria under optimal conditions of growth.

Thus, these "Superbugs," or antibiotic-resistant bacteria, have been in the news lately. These types of bacteria can cause very difficult to treat infections since conventional antibiotics do not kill them. While most of them can be eradicated, it requires potent (and costly) antibiotics. And most terrifying, we play a role in creating these superbugs. To see how we first need to understand [20] how bacteria reproduce and how they adapt (and share that adaptation

to their surrounding buddies). We face the unwanted phenomenon of antibiotic resistance [21].

Antimicrobial resistance is the ability of a microorganism to survive and multiply in the presence of an antimicrobial agent that would typically inhibit or kill this kind of organism. Antimicrobial resistance is just one of the many adaptive traits that resilient bacterial subpopulations may possess or acquire, enabling them to out-compete and out-survive their microbial neighbors and overcome host strategies against them. This phenomenon is nearly as old as the discovery of antimicrobials themselves, described by pioneers like Ehrlich for trypanosomes⁸ and Fleming for staphylococci¹⁰. What is most alarming today is the rate at which antibiotic resistance often develops and how quickly it spreads across the globe and among different bacteria species.

Antibiotic Resistance

- Antibiotic resistance is a microorganism’s ability to withstand an antibiotic’s effects.
- It is a specific type of drug resistance.
- Antibiotic resistance evolves naturally via natural selection through random mutation, but it could also be engineered by applying evolutionary stress on a population.
- Once such a gene is generated, bacteria can transfer the genetic information, in a horizontal fashion (between individuals) by plasmid exchange.
- A bacterium carries several resistance genes, called multiresistant or, informally, a superbug.
- Causes Antibiotic resistance can also be introduced artificially into a microorganism through transformation protocols.
- This can be a useful way of implanting artificial genes into the microorganism.
- Antibiotic resistance is a consequence of evolution via natural selection.
- The antibiotic action is an environmental pressure; those bacteria which have a mutation allowing them to survive will live on to reproduce.
- They will then pass this trait on to their offspring, which will be a fully resistant generation.

- When used correctly, antibiotics are lifesaving medicines that fight bacterial infections. Antibiotic misuse for example, taking the drugs unnecessarily, taking the wrong antibiotic, or not taking them exactly as prescribed creates fertile ground for antibiotic resistance growth.
- We take antibiotics for granted at our peril. We assume they will always be available and effective when the truth is that deadly bacteria are becoming immune to existing antibiotics faster than we can find new ones.
- At least 80 million antibiotic prescriptions written annually in the United States are unnecessary, and improving antibiotic prescribing is a national priority.
- Some superbugs are present in every infection; by abuse of the drugs, the easy to eradicate “normal” bugs are eliminated, but the superbugs remain to further proliferate in the fast pace of minutes for the appearance of the next generation. In this way, the concentration of the “superbugs” the resistant strands are taking over the bacterial community until there are only “superbugs” in the infection.




Figure 4: Understanding the ‘Superbug’ concept: When humans or animals ingest antibiotics, some of the targeted bacteria survive. These resistant bacteria or ‘superbugs’ are immune to the effects of antibiotics, and then multiply so that the disease no longer responds to treatment. The overuse of antibiotics in farm animals (about 45% of antibiotics in the UK are given to farm animals² with the figure rising to 70-75%³ in the USA) has caused many diseases which pass from animals to humans to become resistant to antibiotics.

<p>Gram-Positive vs, Gram-negative bacteria</p> <p>Gram-positive (St. Streptococcus) These pathogens have a thick, multi-layered peptidoglycan cell wall. They are resistant to many antibiotics.</p> <p>Gram-negative (E. Coli) These pathogens have a thin, single-layered peptidoglycan cell wall. They are more resistant to many antibiotics.</p>	<p>WHO priority pathogens list for R&D of new antibiotics</p> <p>Priority 1: CRITICAL</p> <ol style="list-style-type: none"> 1. <i>Acinetobacter baumannii</i>, carbapenem-resistant 2. <i>Pseudomonas aeruginosa</i>, carbapenem-resistant 3. <i>Enterobacteriaceae</i>, carbapenem-resistant, ESBL-producing <p>Gram-negative bacteria</p>
---	---

Gram-negative bacteria are more intrinsically resistant to antibiotics. They don't absorb the toxin into their insides. Their ability to resist traditional antibiotics make them more dangerous in hospital settings, where patients are weaker and bacteria are stronger. New and very expensive antibiotics have been developed to combat these resistant species, but there remain some superbugs (MDROs) that nothing can kill. Not only do the Gram-negative bacteria's natural defenses keep out these antibiotics, some even have an acquired resistance to antibiotics that make it to their inner cell bodies.

Figure 3: Gram-positive, Gram-negative diagram of differences. One major reason for the proliferation of superbugs is the abuse of antibiotic drugs prescriptions.

Antimicrobial Agent to Fight Bacterial Resistance

Antimicrobial agents (“ANTIBIOTICA”) changed human and animal health systems. This revolutionizes our weapons in the war against infectious disease, resulting in improved survivability. There was a time when the perfect antimicrobial drug, “The magic bullet a search for the perfect drug,” was considered an achievable target [22] for humans and animals. However, this health triumph has been tempered by the subsequent realization that bacterial populations can quickly modify themselves to resist [23].

Shai [24] and Matsuzaki [25] showed that antimicrobial peptides could become selective cell agents.




Figure 5: Mode of action and development of bacterial resistance to antibiotics.

Frequent antibiotic use over long periods puts selective pressure on bacteria and causes resistance to spread. Most bacteria are killed when an antibiotic is used to treat a typical bacterial infection. Sometimes, however, a bacterium with an advantaged life. This bacterium can then reproduce and pass its advantage on, creating many more antibiotic-resistant bacteria.

Antibiotics in the clinical pipeline in 2015
MS Butler et al

Table 1 Antibiotics and β -lactamase inhibitor combinations launched from 2000 to 2015, their antibiotic class, activity spectra, country of first approval, lead source and NP lead source if applicable

Year approved	Drug name ^{a,b}	Class	Bacteria type	Country of first approval	Lead source	NP lead source
2000	Linezolid	Oxazolidinone	G+ve	USA	S	
2001	Tellitromycin	Macrolide	G+ve/G-ve	Germany	NP-derived	Actinomycete
2002	Blapenem	Carbapenem	G+ve/G-ve	Japan	NP-derived	Actinomycete
2002	Ertapenem	Carbapenem	G+ve/G-ve	USA	NP-derived	Actinomycete
2002	Fluorfenoxacin	Fluoroquinolone	G+ve/G-ve	Japan	S	
2002	Pazufloxacin	Fluoroquinolone	G+ve/G-ve	Japan	S	
2002	Balofloxacin	Fluoroquinolone	G+ve/G-ve	South Korea	S	
2003	Daptomycin ^c	Lipopeptide	G+ve	USA	NP	Actinomycete
2004	Gemifloxacin	Fluoroquinolone	G+ve/G-ve	USA	S	
2005	Doripenem	Carbapenem	G+ve/G-ve	Japan	NP-derived	Actinomycete
2005	Tigecycline	Tetracycline	G+ve/G-ve	USA	NP-derived	Actinomycete
2007	Retapamulin ^{d,e}	Pleurotulin	G+ve	USA	NP-derived	Fungus
2007	Garenoxacin	Quinolone	G+ve/G-ve	Japan	S	
2008	Cefepime medocartil	Cephalosporin	G+ve/G-ve	Canada	NP-derived	Fungus
2008	Stafabacin	Fluoroquinolone	G+ve/G-ve	Japan	S	
2009	Tebipenem pivoxil	Carbapenem	G+ve/G-ve	Japan	NP-derived	Actinomycete
2009	Telavancin	Glycopeptide	G+ve	USA	NP-derived	Actinomycete
2009	Antifloxacin	Fluoroquinolone	G+ve/G-ve	China	S	
2009	Bistifloxacin ^f	Fluoroquinolone	G+ve/G-ve	USA	S	
2010	Ceftazidime ceftazidime	Cephalosporin	G+ve/G-ve	USA	NP-derived	Fungus
2011	Fidaxomicin ^g	Tiacumicin	G+ve	USA	NP	Actinomycete
2012	Bedaquiline ^h	Diahydanolone	G+ve (TB)	USA	S	
2012	Perchlorone (1)	Thiosemicarbazone	G+ve (TB)	Russia	S	
2014	Delamanid (2)	Nitroimidazole	G+ve (TB)	Europe	S	
2014	Dalbavancin (3)	Glycopeptide	G+ve	USA	NP-derived	Actinomycete
2014	Oritavancin (4)	Glycopeptide	G+ve	USA	NP-derived	Actinomycete
2014	Tedizolid phosphate (5)	Oxazolidinone	G+ve/G-ve	USA	S	
2014	Ceftolozane (6)/tazobactam ^f (7)	β -Lactam/ β -lactamase inhibitor	G-ve	USA	NP-derived/NP-derived	Fungus/actinomycete
2014	Nemoxacin (8)	Quinolone	G+ve/G-ve	Taiwan	S	
2014	Fluorfenoxacin (9)	Fluoroquinolone	G+ve/G-ve	USA	S	
2015	Ceftazidime ^g (10)+avibactam ^h (11)	β -Lactam+DBO β -lactamase inhibitor	G-ve	USA	NP-derived/S	Fungus
2015	Ozenoxacin (12) ⁱ	Quinolone	G+ve	Japan	S	

Abbreviations: G-ve, Gram negative; G+ve, Gram positive; NP, natural product; S, synthetic; TB, tuberculosis; USA, United States of America.
^aThe structures of the antibiotics approved from 2000 to 2012 can be found in our previous review.²⁴
^bFirst member of a new antibiotic or β -lactamase inhibitor class approved for human therapeutic use.
^cPleurotulin derivatives have been previously used in animal health.
^dApproved for topical use.
^eAvibactam and ceftazidime were first launched in 1992 and 1983, respectively.

Figure 6: Antibiotic agent in pipeline and R&D.

The shortlist in the table above represents some of the newest antibiotic drugs approved for anti-infection treatment. New compounds are isolated, identified, tested, and modified [26]. Please notice the poor yields in antibacterial agents in the last decades. Only a score of novel drugs was found and approved [27]. Those do not provide weapons to fight infections in healthcare installations (nosocomial infections) and give only little hope to the millions suffering from the resistant microbes in most cases, must die while treated in hospitals.




Figure 7: Structures of recently developed antibiotic agents.

One of the reasons is that even the most modern findings in the area are impotent in killing bacteria when resistant strands are the matter.

CRE [28] are a type of bacteria that are highly resistant to many antibiotics. They have earned the name “killer bacteria” and “nightmare bacteria” for a good reason. The death rate for those infected with CRE, or carbapenem-resistant *Enterobacteriaceae* (The *Enterobacteriaceae* are a large family of Gram-negative bacteria) is greater than 40 percent, according to the California Department of Public Health (CDPH), and could be as high as 50 percent, according to the Centers for Disease Control (CDC).

From the perspective of drug-resistant organisms, (CRE) is the most severe threat, the most serious challenge we face to patient safety. These (bacteria) are going to impact significantly the kind of surgeries (and) treatments we can have; we’re entering the post-antibiotic era; that’s a very big problem.

Infections usually occur in hospitals, nursing homes, and other healthcare settings, the CDC said. Members of the general population are generally not at risk.

LAST LINE ANTIBACTERIALS, JUST WHEN NOTHING MORE WORKS
REVIEWS OF ANTI-INFECTION AGENTS • CID 2005;40 (1 May) • 1333


This image shows two rod-shaped bacteria called *Klebsiella pneumoniae* that are resistant to treatment with the “last resort” antibiotic drug called carbapenem. In this image, the mustard-colored bacteria are interacting with the green-colored human white blood cells.

Figure 9: Antibiotics to cure infections caused by resistant bacteria “Last resort”.

In March 2016 [29], the CDC reported: that “superbugs” bacteria that are highly resistant to antibiotics are responsible for one out

of seven infections caught in general hospitals. Causing an annual estimate of 80,000 in the U.S. Several bacterial infections have evolved to ‘deadly invader’ status, and it’s partially our fault. The 18 superbugs identified by the CDC are salmonella, drug-resistant tuberculosis, and a staph bacterium known as MRSA (Methicillin-resistant *Staphylococcus aureus*). These bugs are gaining ‘super-status’ because we’ve been careless and stupid with antibiotics like Colistin, rendering them useless, if not dangerous. In other words, we’re helping create deadly types of bacteria. The revival of Colistin is the rehabilitation of a renal [30] damaging agent, and it is the best drug to apply when there is no other choice.

The emergence of drug-resistant strains of major pathogenic bacteria such as *Staphylococcus aureus* is an increasingly serious public health concern [31]. To evade bacterial drug resistance mechanisms, new effective chemotherapeutic agents, which have novel mechanisms of action as well as different cellular targets compared with conventional antibiotics, need to be developed [2]. The shortage of new antibiotics to combat multidrug-resistant (MDR) strains has led to a renewed interest in polymyxins [32]. Polymyxins are active against MDR Gram-negative bacteria such as *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, and *Enterobacter* species [33]. Early reports described high incidences of nephrotoxicity and neurotoxicity during polymyxin therapy [9], and the use of polymyxins was replaced in the 1970s by antibiotics considered to be less toxic. However, recent studies showed that polymyxins have good effectiveness and are considerably less toxic than reported initially. Cationic Colistin (polymyxin B) was re-introduced as a “last resort” for treating patients with acute infection based on drug-resistant bacteria. However established that the cyclic peptide is very harmful to central organs like heart, liver, kidney brain and is a lethal substance in about 60% of its use causes mortality [34]. Polymyxins, a group of polypeptide antibiotics that consists of 5 chemically different in 1947. Only polymyxin B and polymyxin E (Colistin) have been used extensively worldwide in Colistin was discovered in 1949 and was nonribosomally synthesized by Ba5). *Coli* of colistimethate sodium in 1959. However, then, due to multidrug-resistant (MDR), gram-negative bacteria in patients with cystic fibrosis. However, the emergence of bacteria resistant to most classes of commercially available antibiotics and the shortage of new antimicrobial agents with activity against gram-negative microorganisms has led to the reconsideration of polymyxins as a valuable therapeutic option.



The novel antimicrobial peptide-based Teixobactin was identified [35,36]. Recently, Scientists have discovered an antibiotic capable of fighting infections that kill hundreds of thousands of people each year, a breakthrough that could lead to the field’s first major new drug in more than a quarter-century. The new agent that was isolated, identified and synthesized gives medicine great hope regarding combatting resistant bacteria. Some research groups synthesized Teixobactin and some of its analogs. This awakes the hopes that are centered around the following:

- 1) Selectivity preferred eradication, Gram+ or Gram-.
- 2) Effective eradication is of all bacteria regular and resistant.
- 3) Low toxicity to humans.

Not only one target is attacked by Teixobactin, but multiple targets, and they are all lethal. For bacteria, it will be very hard to modify this target, especially this part of the molecule that Teixobactin binds.

Until the discovery of Teixobactin, the following were the top antibiotics in the clinic:

The last significant new antibiotic, daptomycin, was discovered in the 1980s by Eli Lilly & Co. After being abandoned in early testing, Antibiotic-resistant bacteria kill at least 700,000 people a year, per a U.K. government review. Unchecked, those infections could lead to 10 million more deaths a year by 2050, the report found.

Tigecycline [37] is one of the newest antibiotics to have been released. It has been on the market for years. It includes activity against gram-positive, gram-negatives except for *P. aeruginosa*, many anaerobes, and many atypical pathogens and several resistant pathogens. Because it is not vulnerable to many of the resistance mechanisms that affect the beta-lactam antibiotics, it has potential utility in those situations. It has been approved for use in complicated skin and skin structure infections and for treating complicated intra-abdominal infections due to susceptible pathogens. These are the only two indications that are approved right now. It has very interesting pharmacokinetics and a long half-life. It will be dosed, after a load, twice a day and has a relatively

low serum concentration but very good tissue distribution. Tigecycline is available as an intravenous solution. The primary side effects or adverse reactions that have been seen in clinical trials have been gastrointestinal symptoms, usually nausea.

The hunt [38] for new antibiotics is benefiting from recent technological advances which make it easier to rapidly comb the DNA of different soil organisms, which are otherwise hard to raise in a petri dish.


- Gonorrhoea is the second most common bacterial sexually transmitted infection (STI) in the UK after chlamydia, with almost 35,000 cases reported in England in 2014 [39]. The WHO estimates that 78 million people worldwide contract the disease each year, with most issues affecting young men and women under 25. To control gonorrhoea, we need new tools and systems for better prevention. The treatment is based on earlier diagnosis and more complete tracking and reporting of new infections-excessive use of antibiotics, microbial resistance, and treatment failures.
- Specifically, we need new antibiotics, rapid, accurate, point-of-care diagnostic tests ideally, ones that can predict which antibiotics will work on that particular infection and, longer-term, a vaccine to prevent gonorrhoea.

The soil is a good place to look for new organisms because it is here that bacteria naturally compete for resources and use a range of exotic chemical compounds to kill each other. The paladin chemical, identified by Dr. Sean Brady and his laboratory at Rockefeller University, New York, works by attacking a fundamental step in bacterial growth, essentially interfering with a major building block that the bacteria use to build and repair their outer membrane [40].

In their study, published as a letter in the journal Nature Microbiology, the authors cautioned that it is only effective against one group of bacteria the gram positives, which include MRSA

Cyclic peptides are leading the current anti-resistant antimicrobials. Bactenecin, Teixobactin [41], and the Milacainides [42] and Ranacyclins [43] are the most active that eradicate resistant bacteria strands.

The finding new antibiotics to treat gram-positive infections like MRSA was good news but could not address the most pressing need. Our concern is the so-called gram-negative bacteria that are difficult to treat and where resistance is increasing.



Colistin [44]: The Revival of Polymyxins for Managing Multidrug-Resistant Gram-Negative Bacterial Infections [45].

Gram-negative bacteria cause pneumonia, blood sepsis [46] and urinary tract infections as skin infections. Twenty-four patients (mean age 44.3 years, mean Acute Physiology and Chronic Health Evaluation II score 20.6) received 26 courses of Colistin. Colistin is regarded as one of the last lines of defense against serious diseases, including pneumonia, which other medicines cannot treat. Without these drugs, diseases commonly treatable in the last century will become deadly again.

Clinical response was observed for 73% of the treatments. Survival at 30 days was 57.7%. Deterioration in renal [47] function was observed in 14.3% of 21 patients who were not already receiving renal [48] replacement therapy, but this deterioration had serious clinical consequences in only one case. Colistin was discovered in 1949 and nonribosomally synthesized by *Bacillus polymyxins colistin Koyama* subspecies [49]. Colistin was initially used therapeutically in Japan and in Europe during the 1950s and in the United States in the form of colistimethate sodium in 1959 [6]. However, the intravenous formulations of Colistin and polymyxin B were gradually abandoned. In most parts of the world in the early 1980s because of the reported high incidence of nephrotoxicity. Subsequently, the intravenous use of Colistin was restricted during the past two decades for treating lung infections. Due to multidrug-resistant (MDR), gram-negative bacteria in patients with cystic fibrosis [10-12]. The emergence of bacteria that are resistant to most classes of commercially available antibiotics and the shortage of new antimicrobial agents with activity against gram-negative microorganisms has led to the reconsideration of polymyxins as a valuable therapeutic option. Currently applied Fosfomycin or Colistin may cause renal damage, it, therefore, demands less damaging antibiotic agents. It seems that we need new antibiotics to treat this class.

Carbapenem-Resistant Enterobacteriaceae (Cre) Infection CRE infections [50] are most commonly seen in people exposed to healthcare settings like hospitals and long-term care facilities, such






Figure 11: Antibiotics development in las decades.

as skilled nursing facilities and long-term acute care hospitals. In healthcare settings, CRE infections occur among sick patients receiving treatment for other conditions. Patients whose care requires devices like ventilators (breathing machines), urinary (bladder) catheters, or intravenous (vein) catheters, and patients who are taking long courses of certain antibiotics are among those at risk for CRE infections.

In recent years, carbapenem resistance among Enterobacteriaceae has dramatically increased and represents an important threat to global health.

Some CRE bacteria have become resistant to almost all available antibiotics and can be deadly—one report cites they can contribute to death in up to 50% of patients who become infected. The Therapeutic options for carbapenem-resistant Enterobacteriaceae infections are limited.

Some reports have investigated the clinical efficacy of intravenous Fosfomycin [51] in patients with CRE infections. Michalopoulos et al. reported 11 ICU patients with CRKP infections treated with intravenous Fosfomycin in combination with other antibiotics; the clinical and microbiological outcome was good, with all-cause hospital mortality of 18.2%, and no adverse events.. More recently, Pontikis et al. investigated clinical outcomes of 48 fosfomycin-treated (mainly in combination with Colistin or tigecycline). ICU patients are having XDR fosfomycin-susceptible *P. aeruginosa* (n D 17) and *K. pneumonia* (n D 41) carbapenemase-producing isolates; the authors reported a survival rate of 54.2%, evidence of bacterial eradication in 56.3% of cases, and development of fosfomycin-resistance in 3 cases.




Fosfomycin (also known as phosphomycin or phosphonomycin and the trade names Monurol and Monuril) is a broad-spectrum antibiotic produced by certain *Streptomyces* species, although chemical synthesis can make it.

As a single dose, Fosfomycin is more convenient than multiple-dose therapy norfloxacin for the same antibacterial efficacy. Bioactive Macrocyclic Peptides and Peptide Mimics [52a-c], AIB-based peptide backbone as scaffolds for helical peptide mimics, Antibiotics like Nisin and other peptides and mimics were tested as potent agents for resistant bacteria.


Nisin is a bacteriocin produced by *Lactococcus lactis* subsp. *Latic* that exhibits a broad inhibitory spectrum against gram-positive bacteria. It includes bacterial endospores [53 a,b]. Recent studies have shown that the spectrum of nisin activity can be extended to include gram-negative bacteria. Applying nisin with the chelating

agent EDTA inhibits *Salmonella* species and other gram-negative bacteria.



One of the approaches is to learn about the potential application of short peptide mimics like β -turn mimics, on the recognition with perspective to apply this if future drug design. The appearance of β -turns in protein interaction is far more common than other, like β -turns. Non-covalent [54,55] interactions between the β -turn-mimics and some receptors on the cell wall of bacteria may supply enough energy differences that may allow differentiation between various bacterial transmembrane cell wall receptors [56] due to the receptor and β -turn mimic interactions. The improvement of agent interactions of some β -turn mimics with many classes of proteins that vary in their secondary structure (β -sheets, globular) have been found to rely on the interaction between β -turn mimics and the proteins.

Bacteria Cell Wall and Proteins [57]



Many variants of β -turn mimic, *one count nine β -turn types* [58], have been applied so far in this area of research. It has been reported that Surrogate at the β -turn domain of Gramicidin S increase the biological activity [59]. One can read about benzodiazepines, β -turn mimic Hot=Tap for example (Credit Ref.60).

The lack of production and introduction of the newer and more effective antibiotic/antibacterial drugs in clinical practice in the post-antibiotic golden age [61] has seen an increase in the emergence of the resistant pathogenic bacterial infections creating a significant problem in the global health of humankind. The situation today is that In 2011, an estimated 722,000 [62] patients contracted a disease during a stay in an acute care hospital in the US; 205 Americans die from hospital-acquired infections (hospital-acquired infections HAI, nosocomial infections [63]) every day.

Compounding the antimicrobial drug resistance problem is the immediate threat of reducing the discovery and development of new antibiotics [64,65].

It is now accepted by scientists that many Gram-positive and Gram-negative pathogens communicate via the production and sensing of small. The diffusible signal molecules to coordinate virulence

determinant production [66]. Horizontal genes transfer enables the transfer of resistance from one sort of bacteria to another either by

❖ **Transformation**, which involves uptake of short fragments of naked DNA by naturally transformable bacteria.

❖ **Transduction** involves the transfer of DNA from one bacterium into another via bacteriophages.

❖ **Conjugation** which involves the transfer of DNA via sexual pilus and requires cell-to-cell contact [67] (see cartoon below). Hunting the nightmare bacteria [68], this event, now termed quorum sensing, represents a novel therapeutic target offering the opportunity to attenuate virulence, and thus control infection, by blocking cell-to-cell communication.

HAI Estimates Occurring in US Acute Care Hospitals, 2011	
Major Site of Infection	Estimated No.
Pneumonia	157,500
Gastrointestinal Illness	123,100
Urinary Tract Infections	93,300
Primary Bloodstream Infections	71,900
Surgical site infections from any inpatient surgery	157,500
Other types of infections	118,500
Estimated total number of infections in hospitals	721,800

Mechanism of action

- Despite the growing interest in these peptides, molecular mechanisms of action still remain unclear.
- The frequent occurrence of positively charged residues is an important feature of lytic peptides. It is thought to help the peptide to reach its target, which for most AMPs is believed to be the cytoplasmic membrane.
- This involves binding to LPS by the displacement of divalent cations, such as Mg²⁺ and Ca²⁺, that are essential for the stability of the cell surface and cross-bridging the negative charges of liposaccharides (LPS).

Frequency of aerobic bacteria from postoperative wound infection at Ayder Teaching and Referral Hospital, Mekelle, Ethiopia (January to June 2012)

No.	Gram	Microorganism	Frequency N (%)
1	G+	<i>S. aureus</i>	40 (34.2)
2	G-	<i>Klebsiella</i> spp.	29 (24.8)
3	G+	CoNS ^a	18 (15.4)
4	G-	<i>Proteus</i> spp.	15 (12.8)
5	G-	<i>P. aeruginosa</i> sp	11 (9.4)
6	G-	<i>E. coli</i>	6 (5.1)
7		<i>Citrobacter</i> spp.	4 (3.4)
		Total	123 (100)

Figure 12: The frequency of aerobic bacteria from postoperative wound infection at Ayder Teaching and Referral Hospital, Mekelle, Ethiopia (January to June 2012) [69].

The wall-building teichoic acids are found only in certain Gram-positive bacteria [70]. The bacteris such as staphylococci, streptococci, lactobacilli, and Bacillus spp. So far, they have not been found in gram-negative organisms. Teichoic acids are polyol phosphate polymers, with either ribitol or glycerol linked by phosphodiester bonds; their structures are illustrated in Figures

2-9. Substituent groups on the polyol chains can include D-alanine (ester attached), N-acetylglucosamine, N-acetylglucosamine, and glucose is characteristic of the teichoic acid from a bacterial species. It can act as a specific antigenic determinant. Teichoic acids are covalently linked to peptidoglycan. The bacterial wall's highly negatively charged polymers can serve as a cation-sequestering [71].

Assessing Compound Permeability in Gram-Negative Bacteria to Enable Rational Drug Design


In Gram-negative bacteria, the envelope is a sophisticated barrier to protecting the cell against external toxic compounds. Membrane transporters, e.g. porins or efflux pumps, are the main filters regulating various hydrophilic molecules' internal accumulation. Regarding bacterial susceptibility towards antibacterial agents, membrane permeability is part of the early bacterial defense. The bacterium manages the translocation process, influx and efflux, to control various molecules' intracellular concentration. Antibiotics and biocides are substrates of these mechanisms, and the continuing emergence of multidrug-resistant isolates is a growing worldwide health concern. To restore antibiotics' activity, different strategies could be proposed to bypass the bacterial membrane barrier, comprising influx and efflux mechanisms [72].

Accessing drug targets in the cytoplasm of Gram-negative pathogens is difficult because of the permeability barrier that limits the accumulation of promising antibiotics to adequate levels within the cell. The ability to measure compound permeation and accumulation in Gram-negative bacteria is potentially an enabling component of structure-activity relationships that guide rational drug design and optimization. Strategies addressing these challenges and the development of enabling technologies will be discussed.

While antibiotic resistance is increasing rapidly, drug discovery has proven to be extremely difficult. Antibiotic resistance transforms some bacterial infections into deadly medical conditions. A significant challenge in antibiotic discovery is designing potent molecules that enter Gram-negative bacteria and avoid active efflux mechanisms. Critical analysis in rational drug design has been hindered by the lack of adequate analytical tools to analyze the bacterial membrane permeability of small molecules. We demonstrate a gigaohm seal between the nanochannel walls and the loaded bacteria, restricting small molecule transport to only occur through the bacterial cell envelope. Quantifying clindamycin translocation through wild-type and efflux-deficient (Δ tolC) Escherichia coli strains via nanofluidic-interfaced liquid chromatography-mass spectrometry shows higher levels of translocation for wild-type E. coli than for an efflux-deficient strain.

The introduction of the N-CH₃ unit to the Penta peptides surrogates stiffens the structure thereby causes an increase in energy demand for saturation. The fraction of this energy in

Gram-negative is smaller than in Gram-positive due to membrane packing composition. It is easier for the N-CH3 to penetrate the outer membrane in gram-positive bacteria and in Gram-negative. Since saturation is achieved in gram-positive with fewer energy demands, the Gram-positive compared to gram-negative are eradicated in preference (through “snorkeling” [73] for example).



compound number	COMPOUND SEQUENCE	MIC ($\mu\text{g/ml}$)		HEMOLYSIS %
		S.Aureu	E.Coli	
30	S-Lys-S-Trp-17-S-Lys	200	100	<3
31	R-Lys-R-Trp-18-R-Lys	200	125	<3
36	S-Lys-S-Trp-19-S-Lys	75	125	<3
37	R-Lys-R-Trp-20-R-Lys	75	135	11

Table 2
The minimal inhibitory concentration (MIC) refers to the lowest concentration of the antibacterial that stops visible growth





Figure 14: Conclusion from the experiment of N-methylation.

The Gram-positive bacteria are easier to penetrate [74] since the outer membrane is poor in membrane proteins. Small energy changes can become significant for the agent’s travel into the outer membrane in such circumstances. The N-CH₃ are less flexible and therefore penetrates easier to the membrane. Finally, after the surrogates settle in the inner part of the outer membrane, the **Lys** ϵ -amine unit can snorkel [75] out and disintegrate the membranes of both Gram-positive and Gram-negative bacteria. The interactions of an AMP with the membrane can not be explained only by a sequential amino-acid pattern or motif; rather character [76,77].

The interactions of an AMPs surrogates with the membrane can not be explained only by a particular sequential amino-acid pattern or motif. Rather, they originate from a combination of physicochemical and structural features [78]. It includes size, residue composition, overall charge, secondary structure, hydrophobicity, and amphiphilic character [77,78]. Also, interactions with the many components that furnish the architecture of the membranes are crucial. From our experiment, we conclude that the vulnerability of bacteria may depend on small structural

variation in the composition of the biocide [8].



References

1. Naveed-ur-Rehman Siddiqui, Farah Naz Qamar, Humaira Jurair, Anwarul Haque (2014) Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study. BMC Infectious Dis 14:626.
2. <https://longitudeprize.org/antibiotic-resistance-crisis-india>
3. <https://labiotech.eu/antibiotic-resistance-review-biotech/>
4. <https://www.theguardian.com/science/2016/jan/08/otzi-the-icemans-5000-year-old-stomach-bug-sheds-light-on-human-migration>
5. a) Centers for Disease Control and Prevention (1999) National Nosocomial Infections Surveillance (NNIS) System report: data summary from January 1990-May 1999. Am J Infect Control 27:520-532.
b) Centers for Disease Control and Prevention (1999) NNIS Antimicrobial Resistance Report: Vancomycin-Resistant Enterococcus (VRE) Facts. Atlanta, GA: Centers for Disease Control and Prevention.
c) Centers for Disease Control and Prevention (2001) National Nosocomial Infection Surveillance (NNIS) System report: data summary from January 1992-June 2001. Am J Infect Control 29:404-421.
d) Centers for Disease Control and Prevention (2004) Proportion of Healthcare- Acquired S. aureus Infections Resistant to Oxacillin (MRSA) Among ICU Patients, 1989-2003. Atlanta, GA: Centers for Disease Control and Prevention.
6. www.cdc.gov/drugresistance/healthcare/problem.htm.
7. a) Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, et al.(2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36:53-59.
b) Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW (2001) The impact of methicillin resistance in Staphylococcus

aureus bacteremia on patient outcomes: mortality, length of stay and hospital charge. Presented at the 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 22-25.

c) Engemann JJ, Carmeli Y, Cosgrove SE (2003) Adverse clinical and economic outcomes attributable to methicillin resistance among patients with *Staphylococcus aureus* surgical site infection. *Clin Infect Dis* 36:592-598.

d) Salgado CD, Farr BM (2003) Outcomes associated with vancomycin resistant enterococci: a meta-analysis. *Infect Control Hosp Epidemiol* 24:690-698

8. a) L'Héritau F, Alberti C, Cohen Y, Troché G, Moine P, Timsit JF (2005) Nosocomial infection and multidrug-resistant bacteria surveillance in intensive care units: a survey in France. *Infect Control Hosp Epidemiol* 26:13-20.

b) Ward MM, Diekema DJ, Yankey JW (2005) Implementation of strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in U.S. hospitals. *Infect Control Hosp Epidemiol* 26:21-30.

c) Flach SD, Diekema DJ, Yankey JW (2005) Variation in the use of procedures to monitor antimicrobial resistance in U.S. hospitals. *Infect Control Hosp Epidemiol* 26:31-38.

d) Lee TA, Hacek DM, Stroupe KT, Collins SM, Peterson LR (2005) Three surveillance strategies for vancomycin-resistant enterococci in hospitalized patients: detection of colonization efficiency and a cost-effectiveness model. *Infect Control Hosp Epidemiol* 26:39-46.

e) Bolon MK, Arnold AD, Feldman HA (2005) Evaluating vancomycin use at a pediatric hospital: new approaches and insights. *Infect Control Hosp Epidemiol* 26:47-55.

9. Robert A. Bonomo (2000) Multiple Antibiotic-Resistant Bacteria in Long-Term-Care Facilities: An Emerging Problem in the Practice of Infectious Diseases. *Clinical Infect Dis* 31:414-422.

10. Patrice Nordmann, Gaelle Cuzon, Thierry Naas (2009) The real threat of *Klebsiella pneumoniae* carbapenemase producing Bacteria. *Lancet Infect Dis* 9:228-236.

11. a) Benjamin Spangler, Dustin Dovala, William S. Sawyer, Katherine V. Thompson, David A, et al. (2018) Molecular Probes for the Determination of Subcellular Compound Exposure Profiles in Gram-Negative Bacteria. *ACS Infect. Dis*

b) Xian-Zhi Li, a Patrick Plésiat, b Hiroshi Nikaido (2015) The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria"; *Clin Microbiol Rev* 28(2):337-418.

12. a) <https://www.theguardian.com/society/blog/2015/aug/21/antibiotic-resistance-the-race-to-stop-the-silent-tsunami-facing-modern-medicine>.

b) Exner (2017) Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria *GMS Hygiene Infect Contr* 12:2196-5226.

13. a) Centers for Disease Control and Prevention (1999) National Nosocomial Infections Surveillance (NNIS) System report: data summary from January 1990-May 1999. *Am J Infect Control* 27:520-532.

b) Centers for Disease Control and Prevention (1999) NNIS

Antimicrobial Resistance Report: Vancomycin-Resistant Enterococcus (VRE) Facts. Atlanta, GA: Centers for Disease Control and Prevention.

c) Centers for Disease Control and Prevention (2001) National Nosocomial Infection Surveillance (NNIS) System report: data summary from January 1992-June 2001. *Am J Infect Control* 29:404-421.

d) Centers for Disease Control and Prevention (2004) Proportion of Healthcare-Acquired *S. aureus* Infections Resistant to Oxacillin (MRSA) Among ICU Patients, 1989-2003. Atlanta, GA: Centers for Disease Control and Prevention.

14. a) Aly NY, Al-Mousa HH, Al Asar el SM (2008) Nosocomial infections in a medical- surgical intensive care unit. *Med Princ Pract* 17:373-377.

b) Erbay H, Yalcin AN, Serin S, Turgut H, Tomatir E, Cetin B, et al. (2003) Nosocomial infections in intensive care unit in a Turkish university hospital: a 2-year survey. *Intensive Care Med* 29:1482-1488.

15. www.cdc.gov/drugresistance/healthcare/problem.htm.

16. [HTTPS://LONGITUDEPRIZE.ORG/BLOG-POST/10-MOST-DANGEROUS-ANTIBIOTIC-RESISTANT-BACTERIA](https://LONGITUDEPRIZE.ORG/BLOG-POST/10-MOST-DANGEROUS-ANTIBIOTIC-RESISTANT-BACTERIA)

17. <https://www.theguardian.com/society/2017/feb/27/world-health-organisation-12-antibiotic-resistant-bacteria-threat-human-health>

18. <http://amrls.cvm.msu.edu/microbiology/molecular-basis-for-antimicrobial-resistance/acquired-resistance/acquisition-of-antimicrobial-resistance-via-horizontal-gene-transfer>

19. http://textbookofbacteriology.net/growth_3.html

20. Marc JM Bonten, Daren J Austin, Marc Lipsitch (2001) Understanding the Spread of Antibiotic Resistant Pathogens in Hospitals: Mathematical Models as Tools for Control. *Clin Infectious Dis* 33:1739-1746.

21. <http://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance>

22. John Mann (1945) The elusive Magic Bullet". Oxford university press. The pharmacological ideal of a drug able to selectively target a disease without other effects on the body, originally defined by Paul Ehrlich as a drug for antibacterial therapy.

23. <http://amrly.cvm.mbu.edu/microbiology/bacterial-resistance-strategies/introductio>. Accessed January 14, 2015. <http://crstoday.com/articles/2015-feb/bacterial-resistance-develops-through-multiple-mechanisms/> Bacterial Resistance Develops Through Multiple Mechanisms.

24. Papo N, Shai Y (2005) Visions & Reflections Host defense peptides as new weapons in cancer treatment"; *CMLS, Cell. Mol Life Sci* 62:784-790.

25. Katsumi Matsuzaki (2009) Control of cell selectivity of antimicrobial peptides"; *Biochimica et Biophysica Acta* 1788:1687-1692.

26. a) Stephen A Cochrane, Christopher T Lohans, Jeremy R Brandelli, George Mulvey, Glen D Armstrong, et al (2014) Synthesis and Structure-Activity Relationship Studies of N-Terminal Analogues of the Antimicrobial Peptide Tridecaptin A1. *J Med Chem* 57:1127-1131.

b) Nermina Malanovic, Karl Lohner (2016) Gram-positive

- bacterial cell envelopes: The impact on the activity of antimicrobial peptides. *Biochimica et Biophysica Acta* 1858: 936-946.
27. Mark S Butler, Mark AT Blaskovich and Matthew A Cooper (2017) Antibiotics in the clinical pipeline at the end of 2015. *J Antibiotics* 70:3-24.
28. <https://www.usatoday.com/story/news/nation/2012/11/29/bacteria-deadly-hospital-infection/1727667/>
29. https://www.nytimes.com/2016/03/08/upshot/were-losing-the-race-against-antibiotic-resistance-but-theres-also-reason-for-hope.html?_r=0
30. <https://www.theguardian.com/environment/2018/feb/01/indias-farmed-chickens-dosed-with-worlds-strongest-antibiotics-study-finds>
31. Foster TJ (2004) The *Staphylococcus aureus* 'superbug'. *J Clin Invest* 114:1693-1696.
32. a) Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. *Clin Infect Dis* 40:1333-1341
- b) Evans ME, Feola DJ, Rapp RP (1999) Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram negative bacteria. *Ann Pharmacother* 33:960-967
- c) Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. (2006) Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. *Lancet Infect Dis* 6:589-601
- d) Michalopoulos A, Falagas ME (2008) Colistin and polymyxin B in critical care. *Crit Care Clin* 24:377-391.
- e) Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, et al. (2006) In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of *Pseudomonas aeruginosa* and *Acinetobacter baumannii* isolated from intensive care units. *Int J Antimicrob Agents* 27:224-228.
33. Arnold TA, Forrest G, Messmer KJ (2007) Polymyxin antibiotics for gram-negative infections. *Am J Health Syst Pharm* 64: 819-826.
34. Matthew E Falagasa, Panagiota Lourida, Panagiotis Poulidakos, Petros I Rafailidis, Giannoula S Tansarli (2014) Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available Evidence. *Antimicrob Agents Chemother*. February 58:654-663.
35. Tatsushi Mogi, Kiyoshi Kita (2009) Gramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics. *Cell Mol Life Sci* 66:3821-3826.
36. Laura JV Piddock, Teixobactin (2015) the first of a new class of antibiotics discovered by iChip technology?. *Antimicrob Chemother* 70:2679-2680.
37. Matthew W Olson, Alexey Ruzin, Eric Feyfant, Thomas S. Rush, John O'Connell, et al. (2006) Functional, Biophysical, and Structural Bases for Antibacterial Activity of Tigecycline. *Antimicrob Agents Chemother* 50: 2156-2166.
38. a) file:///C:/Users/User/OneDrive/desktop/New%20antibacterials/New%20type%20of%20antibiotic%20discovered%20in%20soil%20in%20breakthrough%20for%20fight%20against%20drug-resistant%20superbugs%20_The%20Independent.pdf
- b) Bradley M Hover, Seong-Hwan Kim, Micah Katz, Zachary Charlop-Powers, Jeremy G. Owen, et al. (2018) Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens. *Nature Microbiol* 3:415-422.
39. <https://www.theguardian.com/society/2017/jul/07/untreatable-gonorrhoea-superbug-spreading-around-world-who-warns>.
40. Anne H Delcour (2008) Outer Membrane Permeability and Antibiotic Resistance. *Biochim Biophys Acta* 1794(5): 808-816.
41. Chuchu Guo, Dhanaraju Mandalapu, Xinjian Ji, Jiangtao Gao, Qi Zhang (2018) Chemistry and Biology of Teixobactin. *Chem Eur J* 24(21):5406-5422.
42. <https://www.pharmazeutische-zeitung.de/index.php?id=74276>
43. M Luisa Mangoni, Niv Papo, Giuseppina Mignogna, David Andreu, Yechiel Shai, et al. (2003) Ranacyclins, a New Family of Short Cyclic Antimicrobial Peptides: Biological Function, Mode of Action, and Parameters Involved in Target Specificity. *Biochemistry* 42 (47):14023-14035.
44. Naveed-ur-Rehman Siddiqui, Farah Naz Qamar, Humaira Jurair and Anwarul Haque (2014) Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study. *BMC Infectious Dis* 14:626.
45. Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. *Semin Clin Infect Dis* 40(9):1333-1341.
46. Nikolaos Markou, Haralampos Apostolakos, Christiana Koumoudiou, Maria Athanasiou, Alexandra Koutsoukou, et al. (2003) Research Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. *Critical Care* 7:R78-R83.
47. Colymycin M parenteral. Bristol, TN: Monarch Pharmaceuticals, 2002.
48. Parker SL, Frantzeskaki F, Wallis SC, Diakaki C, Giamarellou H, et al. (2015) Population pharmacokinetics of fosfomycin in critically ill patients. *Antimicrob Agents Chemother* 59:6471-6476.
49. a) Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC (1970) Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. *Ann Intern Med* 1970; 72:857-868.
- b) Ryan KJ, Schainuck LI, Hickman RO, Striker GE (1969) Colistimethate toxicity: report of a fatal case in a previously healthy child. *JAMA* 207:2099.
- c) Conway SP, Pond MN, Watson A, Etherington C, Robey HL, et al. (1997) Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. *Thorax* 52:987-993.
- d) Cunningham S, Prasad A, Collyer L, Carr S, Lynn IB, et al. (2001) Bronchoconstriction following nebulised colistin in cystic fibrosis. *Arch Dis Child* 2001; 84:432-433.
- e) Ledson MJ, Gallagher MJ, Cowperthwaite C, Convery RP, Walshaw MJ (1998) Four years' experience of intravenous

- colomycin in an adult cystic fibrosis unit. *Eur Respir J* 12:592-594.
50. Sangeeta Sastry, Yohei Doi (2016) Fosfomycin: Resurgence of An Old Companion. *J Infect Chemother* 22(5):273-280.
51. a) Enrico Maria Trecarichi, Mario Tumbarello (2017) Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. *Virulence* 8: 470-484.
- b) Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, et al (2014) Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. *Int J Antimicrob Agents* 43(1):52-59.
- c) Ryota Ito, Mustapha M Mustapha, Adam D. Tomich, Jake D. Callaghan, Christi L. McElheny, et al. (2017) Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal *fosA* Gene. *mBio*. 8(4): e00749-17.
52. a) Rob MJ Liskamp, Dirk TS Rijkers, Saskia E. Bakker (2008) Bioactive Macrocyclic Peptides and Peptide Mimics, Modern Supramolecular Chemistry: Strategies for Macrocyclic Synthesis. Edited by François Diederich, Peter J. Stang, and Rik R. Tykwinski Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
- b) Raja Banerjee, Gautam Basu, Patrick Chene, Siddhartha Roy (2002) Aib-based peptide backbone as scaffolds for helical peptide mimics. *J. Peptide Res* 60:88-94.
- c) Chatterjee C, Paul M, Xie L, van der Donk WA (2005) Biosynthesis and mode of action of antibiotics. *Chem Rev* 105:633-684.
53. a) Klaenhammer TR (1988) Bacteriocins of lactic acid bacteria. *Biochimie* 70:337-349.
- b) Stevens KA, Sheldon BW, Klapes NA, Klaenhammer TR (1991) Nisin treatment for the inactivation of *Salmonella* species and other gram-negative bacteria. *Appl Environ Microbiol* 57:3613-3615.
54. <http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/N/Noncovalent.html>
55. Earl Frieden (1975) Non-covalent interactions: Key to biological flexibility and specificity. *J Chem Educ* 52 (12):754.
56. Ichiro N. Maruyama (2015) Activation of transmembrane cell-surface receptors via a common mechanism? The rotation model. *Bioessays* 37: 959-967.
57. <http://abx4dummies.weebly.com/bacterial-cell-wall.html>
58. <http://nptel.ac.in/courses/104103018/module2/lec8/2.html>
59. Angeles Jimenez, Luis Rivas, Ana I Jimenez, David Andreu, Carlos Cativiela, et al. (2010) Sequence Inversion and Phenylalanine Surrogates at the β -Turn Enhance the Antibiotic Activity of Gramicidin S. *J Med Chem* 53:4119-4129.
60. Bjorn Eckhardt, Wolfgang Grosse, Lars-Oliver Essen, Armin Geyer (2010) Structural characterization of a β -turn mimic within a protein-protein interface. *PNAS* 107:1004187107
61. Julian Davies (2006) Where have All the Antibiotics Gone?. *Can J Infect Dis Med Microbiol* 17(5):287-290.
62. <https://www.cdc.gov/hai/surveillance/index.html>
63. a) Bryant, Kristina A Woods, Charles R (2008) Healthcare-Acquired Infections Due to Gram-Positive Bacteria. *Pediatric Infectious Disease J* 27(5):455-456.
- b) Anton Y Peleg, David C. Hooper (2010) Hospital-Acquired Infections Due to Gram-Negative Bacteria. *N Engl J Med* 362(19):1804-1813.
- c) <http://www.reuters.com/article/us-usa-hospital-infections-idUSBREA2P1DG20140326>
64. a) Jiexi Yan, Kairong Wang, Wen Dang, Ru Chen, Junqiu Xie, et al. (2013) Two Hits Are Better than One: Membrane-Active and DNA Binding Related Double-Action Mechanism. *Agents Chemother*. January 57:220-228.
- b) Ghosh A, Kar RK, Jana J, Saha A, Jana B, et al. (2014) Indolicidin targets duplex DNA: Structural and mechanistic insight through a combination of spectroscopy and microscopy. *Chem Med Chem* 9:2052-2058.
- c) Kim A Brogden (2005) Antimicrobial Peptides: Pore Formers Or Metabolic Inhibitors In Bacteria? *Nature Reviews Microbiol* 3:238-250.
65. Jae-Young Je, Se-Kwon Kim (2006) Chitosan Derivatives Killed Bacteria by Disrupting the Outer and Inner Membrane. *J Agric Food Chem* 54:6629-6633.
66. Edwin S Van Amersfoort, Theo JC Van Berkel, Johan Kuiper (2003) Receptors, Mediators, and Mechanisms Involved in Bacterial Sepsis and Septic Shock. *Clin Microbiol Rev* 16:379-414.
67. a) Howard Ochman, Jeffrey G. Lawrence, Eduardo A. Groisman (2000) Lateral gene transfer and the nature of bacterial innovation. *Nature* 405:299-304.
- b) <http://amrls.cvm.msu.edu/microbiology/molecular-basis-for-antimicrobial-resistance/acquired-resistance/acquisition-of-antimicrobial-resistance-via-horizontal-gene-transfer>.
- c) Sara Dominguez, Klaus Harms, Florian Fricke W, Pal J. Johnsen, Gabriela J. da Silva, et al. (2012) Natural Transformation Facilitates Transfer of Transposons, Integrins and Gene Cassettes between Bacterial Species. *PLoS Pathog* 8(8):e1002837.
68. <http://www.pbs.org/wgbh/frontline/film/hunting-the-nightmare-bacteria>
69. Reiyee Esayas Mengesha, Berhe Gebre-Slassie Kasa, Muthupandian Saravanan, Derbew Fikadu Berhe, Araya Gebreyesus Wasihu (2014) Aerobic bacteria in post surgical wound infections and pattern of their antimicrobial susceptibility in Ayder Teaching and Referral Hospital, Mekelle, Ethiopia. *BMC Research Notes* 7:575.
70. William Wiley Navarre, Olaf Schneewind (1999) Surface Proteins of Gram-Positive Bacteria and Mechanisms of Their Targeting to the Cell Wall Envelope. *Microbiol Mol Biol Rev* 63(1): 174-229.
71. <http://intranet.tdmu.edu.ua/data/cd/disk2/ch002.htm>
72. Jean-Michel Bolla, Sandrine Alibert-Franco, Jadwiga Handzlik, Jacqueline Chevalier, Abdallah Mahamoud, et al. (2011) Strategies for bypassing the membrane barrier in multidrug resistant Gram-negative bacteria. *FEBS Letters* 585(11):1682-1690.
73. Vinod K. Mishra, Mayakonda N. Palgunachari, Jere P. Segrest, GM Anantharamaiah S (1994) Interactions of Synthetic Peptide Analogs of the Class A Amphipathic Helix with Lipids, evidence for the snorkel hypothesis. *J of Biol Chem* 269:7185-7191.
74. Hiroshi Nikaido (2003) Molecular Basis of Bacterial Outer Membrane Permeability Revisited. *Microbiol Mol Biol Rev*

67:593-656.

75. Ralf Koebnik, Kaspar P. Locher and Patrick Van Gelder (2000) Structure and function of bacterial outer membrane proteins: barrels in a nutshell. *Molecular Microbiology* 37(2):239-253.

76. Hall K, Mozsolits H, Aguilar MI (2004) Surface plasmon resonance analysis of antimicrobial peptide-membrane interactions: affinity and mechanism of action. *Lett Pept Sci* 10:475-485.

77. Boman HG (2003) Antibacterial peptides: basic facts and emerging concepts. *J Intern Med* 254:197-215.

78. Hall K, Mozsolits H, Aguilar MI (2004) Surface plasmon resonance analysis of antimicrobial peptide-membrane interactions: affinity and mechanism of action. *Lett Pept Sci* 10:475-485.

Copyright: ©2022: Shimon Shatzmiller, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.